Premier Explosives Ltd.
PREMEXPLN.BO News Today: Stay Updated with the Latest Premier Explosives Ltd. News in Real Time
Find PREMEXPLN.BO news now at Meyka AI. Stay informed with the latest Premier Explosives Ltd. stocks updates, including price news, market analysis, and expert insights.
^GSPC Today, April 11: Epstein Hearings Talk Lifts Policy Risk
^GSPC edges lower as House Oversight hearings talk and Amanda Ungaro coverage raise policy risk. What GB investors should watch today: levels, volatility, and headline triggers.
A31.SI Stock Surges 3.49% in Pre-Market: Addvalue Technologies Gains Momentum
A31.SI stock rises 3.49% to SGD 0.089 in pre-market trading with 93.56M shares traded on Singapore Exchange.
JNJ Analyst Rating Maintained at Overweight by Morgan Stanley April 2026
Morgan Stanley maintains JNJ analyst rating at Overweight, raises price target to $267 on April 10, 2026.
SNOW Stock Today: April 11 Agentic AI Fears Drive 10% Selloff
Snowflake stock today slumps as agentic AI fears spark a SaaS selloff. We cover price action, technicals, fundamentals, analyst views, and key catalysts for Australian investors.
SIZE.NE Stock Surges 16.67% on Volume Spike: Major Precious Metals Corp. Analysis
SIZE.NE stock surges 16.67% on 494,426-share volume spike. Major Precious Metals Corp. trading on NEO amid sector strength.
April 11: BoE Warns Iran War Could Spark 2008-Style Financial Crisis
BoE’s Andrew Bailey warns the Iran conflict could trigger a 2008-style financial crisis via stress in the $3 trillion private credit market. What this means for UK mortgage rates, gilts, and investor
Gaxi Funding April 11: ¥425M Series B to Expand Scholarship DX
Gaxi Series B funding: Japan’s leading scholarship platform raises ¥425M in a first close to scale scholarship DX tools. What it means for Japan edtech, CSR, and investors.
PHASQ stock plunges 99% in 2026: PhaseBio Pharmaceuticals bankruptcy aftermath
PHASQ stock down 99% after PhaseBio Pharmaceuticals Chapter 11 bankruptcy. Current price USD 0.000001. Analysis and outlook.
LBRX Upgraded to Buy by Craig-Hallum on April 10, 2026
Craig-Hallum initiates LBRX analyst rating with Buy coverage on April 10, 2026, signaling bullish outlook for LB Pharmaceuticals.